CoChat

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice

Open access

Abstract

Senotherapy targeting for senescent cells is designed to attenuate age-related dysfunction. Senescent T cells, defined as CD4 + CD44 high CD62L low PD-1 + CD153 + cells, accumulate in visceral adipose tissues (VAT) in obese individuals. Here, we show the long-lasting effect of using CD153 vaccination to remove senescent T cells from high-fat diet (HFD)-induced obese C57BL/6J mice. We administered a CD153 peptide-KLH (keyhole limpet hemocyanin) conjugate vaccine with Alhydrogel (CD153-Alum) or CpG oligodeoxynucleotide (ODN) 1585 (CD153-CpG) and confirmed an increase in anti-CD153 antibody levels that was sustained for several months. After being fed a HFD for 10–11 weeks, adipose senescent T cell accumulation was significantly reduced in the VAT of CD153-CpG-vaccinated mice, accompanied by glucose tolerance and insulin resistance. A complement-dependent cytotoxicity (CDC) assay indicated that the mouse IgG2 antibody produced in the CD153-CpG-vaccinated mice successfully reduced the number of senescent T cells. The CD153-CpG vaccine is an optional tool for senolytic therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-16347-w

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Development of CD153 vaccine. a–c Seven-week-old C57BL/6J mice were immunized with the CD153-Alum vaccine (#a–e) or the KLH-Alum vaccine on days 0 and 14. a The titer against recombinant mouse CD153 is expressed as the OD at 450 nm at 28 days postimmunization. #a–e, n = 4, 6, 6, 3, 3, respectively; KLH, n = 3. b The antibody recognizes the rmCD153 protein by western blot analysis. As a negative control, 100 ng of rmOPN was applied to lane 1, while 30 and 100 ng of rmCD153 were applied to lanes 2 and 3, respectively. c The levels of IgG1 (Th2 response) and IgG2b, IgG2c, and IgG3 (Th1 response) in mice immunized with the CD153#D-Alum vaccine (n = 3) or the CD153#D-CpG vaccine (n = 6) on days 0, 14, and 28. Sera were collected on day 42. IgG1, p = 0.011; IgG2b, p = 0.0067; IgG2c, p = 0.0027; IgG3, p = 0.0029. Left; The titer against CD153-BSA is expressed as the half-maximal binding (OD 50%). Right; ratio of the titer against CD153-BSA-specific IgG2b:IgG1 (p = 0.022), IgG2c:IgG1 (p = 0.0091) and IgG3:IgG1 (p = 0.21). d The proportions of CD153+ senescent T cells in splenic tissues and VAT of male C57BL/6J mice at the ages of 20 and 3 months (normal diet). Senescent T cells were defined as PD-1+ CD153+ cells in CD4+, CD44hi, CD62Llo cells. e The proportion of senescent T cells induced by R848 administration in splenic tissues of male C57BL/6J mice (n = 6 in each group) at the ages of 18 weeks with or without the CD153-CpG vaccine or the KLH-CpG vaccine. PBS vs. R848, p = 0.0086; PBS vs. KLH-CpG, p = 0.0052; PBS vs. CD153-CpG, p = 0.98; R848 vs. KLH-CpG, p > 0.99; R848 vs. CD153-CpG, p = 0.020; KLH-CpG vs. CD153-CpG, p = 0.012. All the data are expressed as the mean ± SEM. Statistical evaluation was performed by one sided (a) and by two sided (c, e); analysis of variance (ANOVA) test (a); unpaired two-tailed t-test (c), natural logarithmic transformation; Tukey’s multiple comparison test e; *p < 0.05; **p < 0.01; ****p < 0.0001; ND, not detected.
Fig. 1 Development of CD153 vaccine. a–c Seven-week-old C57BL/6J mice were immunized with the CD153-Alum vaccine (#a–e) or the KLH-Alum vaccine on days 0 and 14. a The titer against recombinant mouse CD153 is expressed as the OD at 450 nm at 28 days postimmunization. #a–e, n = 4, 6, 6, 3, 3, respectively; KLH, n = 3. b The antibody recognizes the rmCD153 protein by western blot analysis. As a negative control, 100 ng of rmOPN was applied to lane 1, while 30 and 100 ng of rmCD153 were applied to lanes 2 and 3, respectively. c The levels of IgG1 (Th2 response) and IgG2b, IgG2c, and IgG3 (Th1 response) in mice immunized with the CD153#D-Alum vaccine (n = 3) or the CD153#D-CpG vaccine (n = 6) on days 0, 14, and 28. Sera were collected on day 42. IgG1, p = 0.011; IgG2b, p = 0.0067; IgG2c, p = 0.0027; IgG3, p = 0.0029. Left; The titer against CD153-BSA is expressed as the half-maximal binding (OD 50%). Right; ratio of the titer against CD153-BSA-specific IgG2b:IgG1 (p = 0.022), IgG2c:IgG1 (p = 0.0091) and IgG3:IgG1 (p = 0.21). d The proportions of CD153+ senescent T cells in splenic tissues and VAT of male C57BL/6J mice at the ages of 20 and 3 months (normal diet). Senescent T cells were defined as PD-1+ CD153+ cells in CD4+, CD44hi, CD62Llo cells. e The proportion of senescent T cells induced by R848 administration in splenic tissues of male C57BL/6J mice (n = 6 in each group) at the ages of 18 weeks with or without the CD153-CpG vaccine or the KLH-CpG vaccine. PBS vs. R848, p = 0.0086; PBS vs. KLH-CpG, p = 0.0052; PBS vs. CD153-CpG, p = 0.98; R848 vs. KLH-CpG, p > 0.99; R848 vs. CD153-CpG, p = 0.020; KLH-CpG vs. CD153-CpG, p = 0.012. All the data are expressed as the mean ± SEM. Statistical evaluation was performed by one sided (a) and by two sided (c, e); analysis of variance (ANOVA) test (a); unpaired two-tailed t-test (c), natural logarithmic transformation; Tukey’s multiple comparison test e; *p < 0.05; **p < 0.01; ****p < 0.0001; ND, not detected.CC BY · PubMed Central
Fig. 2 Metabolic analysis of HFD-loaded mice immunized with the CD153 vaccine. a Time course of HFD loading and injection of vaccines. Mice immunized with the CD153-Alum vaccine or the KLH-Alum vaccine (n = 3 in each group) were vaccinated at the ages of 7, 9, 11, 13, and 15 weeks and fed a HFD from the age of 15 weeks. Mice immunized with the CD153-CpG vaccine or the KLH-CpG vaccine (n = 6 in each group) were vaccinated at the ages of 7, 9, 11, and 16 weeks and fed a HFD from the age of 11 weeks. Mice in the ND (normal diet) control group (n = 5) were unvaccinated and fed a ND, while mice in the HFD control group (n = 6) were unvaccinated and fed a HFD from the age of 11 weeks. b Titers against CD153-BSA in mice immunized with the CD153-Alum vaccine (n = 3) or the CD153-CpG vaccine (n = 6) during HFD loading. Titers are expressed as the half-maximal binding (OD 50%). c The body weights of mice in the ND control group (n = 5), mice in the HFD control group (n = 6), and mice immunized with the CD153-CpG vaccine (n = 6) or the KLH-CpG vaccine (n = 6) before metabolic measurement. Asterisk indicates the CD153-CpG group vs. the KLH-CpG group. d The weekly average amount of HFD intake per mouse (g/week/mouse) in mice immunized with the CD153-CpG vaccine or the KLH-CpG vaccine during HFD loading. Data were collected from 11 to 19 weeks of age (n = 8 in each group). e The average VO2 values during the light (8:00–20:00) and dark (20:00–8:00) periods in mice in the HFD control group (n = 6) and in mice immunized with the CD153-CpG vaccine (n = 6) or the KLH-CpG vaccine (n = 6) at the age of 21–22 weeks. All the data are expressed as the mean ± SEM. Statistical evaluation was performed by two sided; Tukey’s multiple comparison test (c, d); Bonferroni correction, HFD vs. KLH-CpG vs. CD153-CpG (e); *p < 0.05; **p < 0.01; ***p < 0.001.
Fig. 2 Metabolic analysis of HFD-loaded mice immunized with the CD153 vaccine. a Time course of HFD loading and injection of vaccines. Mice immunized with the CD153-Alum vaccine or the KLH-Alum vaccine (n = 3 in each group) were vaccinated at the ages of 7, 9, 11, 13, and 15 weeks and fed a HFD from the age of 15 weeks. Mice immunized with the CD153-CpG vaccine or the KLH-CpG vaccine (n = 6 in each group) were vaccinated at the ages of 7, 9, 11, and 16 weeks and fed a HFD from the age of 11 weeks. Mice in the ND (normal diet) control group (n = 5) were unvaccinated and fed a ND, while mice in the HFD control group (n = 6) were unvaccinated and fed a HFD from the age of 11 weeks. b Titers against CD153-BSA in mice immunized with the CD153-Alum vaccine (n = 3) or the CD153-CpG vaccine (n = 6) during HFD loading. Titers are expressed as the half-maximal binding (OD 50%). c The body weights of mice in the ND control group (n = 5), mice in the HFD control group (n = 6), and mice immunized with the CD153-CpG vaccine (n = 6) or the KLH-CpG vaccine (n = 6) before metabolic measurement. Asterisk indicates the CD153-CpG group vs. the KLH-CpG group. d The weekly average amount of HFD intake per mouse (g/week/mouse) in mice immunized with the CD153-CpG vaccine or the KLH-CpG vaccine during HFD loading. Data were collected from 11 to 19 weeks of age (n = 8 in each group). e The average VO2 values during the light (8:00–20:00) and dark (20:00–8:00) periods in mice in the HFD control group (n = 6) and in mice immunized with the CD153-CpG vaccine (n = 6) or the KLH-CpG vaccine (n = 6) at the age of 21–22 weeks. All the data are expressed as the mean ± SEM. Statistical evaluation was performed by two sided; Tukey’s multiple comparison test (c, d); Bonferroni correction, HFD vs. KLH-CpG vs. CD153-CpG (e); *p < 0.05; **p < 0.01; ***p < 0.001.CC BY · PubMed Central
Fig. 3 Glucose tolerance and insulin sensitivity in HFD-loaded mice immunized with CD153 vaccine. a–c Blood glucose concentrations and percent basal glucose in mice immunized with the Alum-conjugated vaccine (CD153-Alum or KLH-Alum) (a; n = 3 in each group) or the CpG-conjugated vaccine (CD153-CpG or KLH-CpG) (b; n = 6 in each group) as determined by the intraperitoneal insulin tolerance test (ipITT). Mice in both the ND (normal diet, n = 5) and HFD (high-fat diet, n = 6) control groups were treated in a manner similar to the vaccinated group. Asterisk indicates the CD153-CpG group vs. the KLH-CpG group. c Area under the curve (AUC) of blood glucose levels as determined by the ITT. The AUC was estimated using the trapezoidal rule. d–f Blood glucose concentrations in mice immunized with the Alum-conjugated vaccine (d; n = 3 in each group) or the CpG-conjugated vaccine (e; n = 6 in each group) as determined by the oral glucose tolerance test (OGTT). Mice in both the ND (normal diet, n = 5) and HFD (high-fat diet, n = 6) control groups were treated in a manner similar to the vaccinated group. Asterisk indicates the CD153-CpG group vs. the KLH-CpG group. Dagger indicates the CD153-CpG group vs. the HFD control group. f AUC of blood glucose levels as determined by the OGTT. The AUC was estimated using the trapezoidal rule. g HOMA-IR index after 6 h of fasting. Alum-conjugated vaccine group, n = 3 in each group; CpG-conjugated vaccine group, n = 6 in each group; ND control group, n = 5; HFD control group, n = 6. All the data are expressed as the mean ± SEM. Statistical evaluation was performed by two sided; unpaired two-tailed t-test, KLH-Alum vs. CD153-Alum (c, f, g); Bonferroni correction, HFD vs. KLH-CpG vs. CD153-CpG (C, F and G); Tukey’s multiple comparison test (a, b, d, e); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ††††p < 0.0001.
Fig. 3 Glucose tolerance and insulin sensitivity in HFD-loaded mice immunized with CD153 vaccine. a–c Blood glucose concentrations and percent basal glucose in mice immunized with the Alum-conjugated vaccine (CD153-Alum or KLH-Alum) (a; n = 3 in each group) or the CpG-conjugated vaccine (CD153-CpG or KLH-CpG) (b; n = 6 in each group) as determined by the intraperitoneal insulin tolerance test (ipITT). Mice in both the ND (normal diet, n = 5) and HFD (high-fat diet, n = 6) control groups were treated in a manner similar to the vaccinated group. Asterisk indicates the CD153-CpG group vs. the KLH-CpG group. c Area under the curve (AUC) of blood glucose levels as determined by the ITT. The AUC was estimated using the trapezoidal rule. d–f Blood glucose concentrations in mice immunized with the Alum-conjugated vaccine (d; n = 3 in each group) or the CpG-conjugated vaccine (e; n = 6 in each group) as determined by the oral glucose tolerance test (OGTT). Mice in both the ND (normal diet, n = 5) and HFD (high-fat diet, n = 6) control groups were treated in a manner similar to the vaccinated group. Asterisk indicates the CD153-CpG group vs. the KLH-CpG group. Dagger indicates the CD153-CpG group vs. the HFD control group. f AUC of blood glucose levels as determined by the OGTT. The AUC was estimated using the trapezoidal rule. g HOMA-IR index after 6 h of fasting. Alum-conjugated vaccine group, n = 3 in each group; CpG-conjugated vaccine group, n = 6 in each group; ND control group, n = 5; HFD control group, n = 6. All the data are expressed as the mean ± SEM. Statistical evaluation was performed by two sided; unpaired two-tailed t-test, KLH-Alum vs. CD153-Alum (c, f, g); Bonferroni correction, HFD vs. KLH-CpG vs. CD153-CpG (C, F and G); Tukey’s multiple comparison test (a, b, d, e); *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ††††p < 0.0001.CC BY · PubMed Central
Fig. 4 Effect of the CD153-CpG vaccine on CD153+ senescent T cells induced by HFD loading. a The proportions of senescent T cells induced by HFD loading in the VAT of mice immunized with the Alum-conjugated vaccine or the CpG-conjugated vaccine. Senescent T cells were defined as PD-1+ CD153+ cells in CD4+, CD44hi, CD62Llo cells. Alum-conjugated vaccine group, n = 3 in each group; CpG-conjugated vaccine group, n = 6 in each group; ND control group, n = 5; HFD control group, n = 6. b The CDC activity of the CD153 vaccine-induced antibody was assessed (n = 3 each sample) using 2 × 104 LPS-stimulated RAW 264.7 cells. The vaccine-induced IgG antibodies used were purified from the sera of HFD-loaded mice at the age of 22–25 weeks immunized with the CD153-Alum vaccine, CD153-CpG vaccine, KLH-Alum vaccine or KLH-CpG vaccine. N, no stimulation with antibody; P, 100 µg/ml anti-mouse MHC class I antibody (H-2Kd/H-2Dd); closed right triangle, the concentrations of purified IgG antibodies; opened right triangle, the concentrations of anti-mouse CD153 antibody (10, 30, 100 µg/ml, respectively). c, d VAT were collected from the four groups of mice (ND control group, HFD control group, KLH-CpG vaccine group, and CD153-CpG vaccine group; n = 3 in each group) according to the time course of HFD loading and injection of vaccines. c Quantification of macrophages in the crown-like structures among the four groups. HFD vs. KLH-CpG, p = 0.11; HFD vs. CD153-CpG, p = 0.0041; KLH-CpG vs. CD153-CpG, p = 0.15. 40–50 fields per sample, F4/80 (brown); scale bars: 100 µm. d Quantification of CD153-positive cells in the crown-like structures among the four groups. HFD vs. KLH-CpG, p = 0.024; HFD vs. CD153-CpG, p = 0.0015; KLH-CpG vs. CD153-CpG, p = 0.20. 40–50 fields per sample, CD153 (brown); scale bars: 100 µm. All the data are expressed as the mean ± SEM. Statistical evaluation was performed by two-sided; unpaired two-tailed t-test, KLH-Alum vs. CD153-Alum (a); Bonferroni correction, ND vs. HFD (a), HFD vs. KLH-CpG vs. CD153-CpG (a, c, d); *p < 0.05; **p < 0.01; n.s. not significant.
Fig. 4 Effect of the CD153-CpG vaccine on CD153+ senescent T cells induced by HFD loading. a The proportions of senescent T cells induced by HFD loading in the VAT of mice immunized with the Alum-conjugated vaccine or the CpG-conjugated vaccine. Senescent T cells were defined as PD-1+ CD153+ cells in CD4+, CD44hi, CD62Llo cells. Alum-conjugated vaccine group, n = 3 in each group; CpG-conjugated vaccine group, n = 6 in each group; ND control group, n = 5; HFD control group, n = 6. b The CDC activity of the CD153 vaccine-induced antibody was assessed (n = 3 each sample) using 2 × 104 LPS-stimulated RAW 264.7 cells. The vaccine-induced IgG antibodies used were purified from the sera of HFD-loaded mice at the age of 22–25 weeks immunized with the CD153-Alum vaccine, CD153-CpG vaccine, KLH-Alum vaccine or KLH-CpG vaccine. N, no stimulation with antibody; P, 100 µg/ml anti-mouse MHC class I antibody (H-2Kd/H-2Dd); closed right triangle, the concentrations of purified IgG antibodies; opened right triangle, the concentrations of anti-mouse CD153 antibody (10, 30, 100 µg/ml, respectively). c, d VAT were collected from the four groups of mice (ND control group, HFD control group, KLH-CpG vaccine group, and CD153-CpG vaccine group; n = 3 in each group) according to the time course of HFD loading and injection of vaccines. c Quantification of macrophages in the crown-like structures among the four groups. HFD vs. KLH-CpG, p = 0.11; HFD vs. CD153-CpG, p = 0.0041; KLH-CpG vs. CD153-CpG, p = 0.15. 40–50 fields per sample, F4/80 (brown); scale bars: 100 µm. d Quantification of CD153-positive cells in the crown-like structures among the four groups. HFD vs. KLH-CpG, p = 0.024; HFD vs. CD153-CpG, p = 0.0015; KLH-CpG vs. CD153-CpG, p = 0.20. 40–50 fields per sample, CD153 (brown); scale bars: 100 µm. All the data are expressed as the mean ± SEM. Statistical evaluation was performed by two-sided; unpaired two-tailed t-test, KLH-Alum vs. CD153-Alum (a); Bonferroni correction, ND vs. HFD (a), HFD vs. KLH-CpG vs. CD153-CpG (a, c, d); *p < 0.05; **p < 0.01; n.s. not significant.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 171

Metadata

Authors
Yoshida, S., Nakagami, H., Hayashi, H., Ikeda, Y., Sun, J., Tenma, A., Tomioka, H., Kawano, T., Shimamura, M., Morishita, R., & Rakugi, H.
Affiliations
The University of Osaka (JP)
Venue
Nature Communications
Published
2020-05-18
Volume
11
Issue
1
Pages
2482-2482
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3025956887
Cited by
161
References
30
Citations by year
2026: 28 · 2025: 35 · 2024: 40 · 2023: 18 · 2022: 21 · 2021: 16 · 2020: 3
FWCI
8.72
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
MEXT | Japan Society for the Promotion of Science (JP15K15310)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
senolytic therapy, senescent T cells, T cell senescence, visceral adipose tissue, obesity, high-fat diet, CpG oligodeoxynucleotides, Alhydrogel, glucose tolerance, insulin resistance, complement-dependent cytotoxicity
MeSH terms
Adipose Tissue, Animals, Blood Glucose, Female, Glucose Tolerance Test, Immunization, Insulin Resistance, Male, Mice, Inbred C57BL, Oligodeoxyribonucleotides, Time Factors, Vaccines, Cellular Senescence, CD30 Ligand, Diet, High-Fat

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice. https://app.cochat.ai/papers/10.1038/s41467-020-16347-w
The paper
Yoshida, S., Nakagami, H., Hayashi, H., Ikeda, Y., Sun, J., Tenma, A., Tomioka, H., Kawano, T., Shimamura, M., Morishita, R., & Rakugi, H. (2020). The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice. Nature Communications. https://doi.org/10.1038/s41467-020-16347-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.